Longeveron (LGVN) news
Recent news
Longeveron - LaroMestrocel maintains favorable safety profile with 644 patients treated
Longeveron Inc. (NASDAQ: LGVN) has reported that its investigational stem cell therapy, laromestrocel (Lomecel-B®), has maintained a favorable safety profile across clinical trials involving 644 patients treated to date. The data, drawn from multiple clinical programs, indicate that laromestrocel…
AInvest Wire · Sep 16, 2026Longeveron - Company initiates process to optimize cost containment and maximize shareholder value
AInvest Wire · Sep 16, 2026Longeveron - No deaths in LaroMestrocel-treated patients over 12 months
AInvest Wire · Sep 16, 2026Longeveron - Elpis II trial did not meet primary endpoint of rVEF improvement at month 12
AInvest Wire · Sep 16, 2026Longeveron announces topline results from Elpis II phase 2B clinical trial evaluating LaroMestrocel as a potential treatment for hypoplastic left heart syndrome (HLHS)
Longeveron Inc. (NASDAQ: LGVN) has announced the topline results from its Phase 2b clinical trial, ELPIS II, evaluating laromestrocel (Lomecel-B®) as a potential treatment for hypoplastic left heart syndrome (HLHS), a rare and life-threatening congenital heart defect. The trial, which enrolled 40…
AInvest Wire · Sep 16, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.